藤野 初江HATSUE FUJINO

Last Updated :2021/07/02

所属・職名
病院(医) 助教
メールアドレス
fujino920hiroshima-u.ac.jp
自己紹介
肝炎ウイルス、肝癌に関する研究・診療を行っています。

基本情報

学歴

  • 広島大学, 医学部, 医学科, 日本, 2001年04月, 2007年03月
  • 広島大学, 大学院医歯薬保健学研究科, 博士課程医歯薬学専攻, 日本, 2013年04月, 2017年03月

学位

  • 博士(医学) (広島大学)

研究分野

  • 医歯薬学 / 内科系臨床医学 / 消化器内科学

研究キーワード

  • 肝炎ウイルス
  • 肝硬変

所属学会

  • 日本内科学会
  • 日本消化器病学会
  • 日本消化器内視鏡学会
  • 日本肝臓学会

研究活動

学術論文(★は代表的な論文)

  1. A case of advanced HCC treated with lenvatinib after hepatic arterial infusion chemotherapy combined with radiation therapy treatment for portal vein tumor thrombosis in the main trunk., Clin J Gastroenterol.
  2. Complete response to pembrolizumab in advanced hepatocellular carcinoma with microsatellite instability., Clin J Gastroenterol.
  3. ★, Role of 3-D conformal radiotherapy for major portal vein tumor thrombosis combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma, HEPATOLOGY RESEARCH, 45巻, 6号, pp. 607-617, JUN 2015
  4. Risk factors for exacerbation of gastroesophageal varices and portosystemic encephalopathy during treatment with nucleos(t)ide analogs for hepatitis B virus-related cirrhosis, HEPATOLOGY RESEARCH, 48巻, 4号, pp. 264-274, MAR 2018
  5. Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy, JOURNAL OF GASTROENTEROLOGY, 53巻, 1号, pp. 107-118, JAN 2018
  6. ★, Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C, JOURNAL OF GASTROENTEROLOGY, 49巻, 12号, pp. 1548-1556, DEC 2014
  7. The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy, PLOS ONE, 12巻, 8号, AUG 10 2017
  8. The association between serum cytokine and chemokine levels and antiviral response by entecavir treatment in chronic hepatitis B patients, Antiviral Therapy, 23巻, 3号, pp. 239-248
  9. The relationship between HBcrAg and HBV reinfection in HBV related post-liver transplantation patients, JOURNAL OF GASTROENTEROLOGY, 52巻, 3号, pp. 366-375, MAR 2017
  10. Effects of ITPA polymorphism on decrease of hemoglobin during simeprevir, peg-interferon, and ribavirin combination treatment for chronic hepatitis C, HEPATOLOGY RESEARCH, 46巻, 12号, pp. 1256-1263, NOV 2016
  11. Improvement of renal dysfunction in a patient with hepatitis C virus-related liver cirrhosis by daclatasvir and asunaprevir combination therapy: A case report, HEPATOLOGY RESEARCH, 46巻, 9号, pp. 944-948, AUG 2016
  12. Development of hepatocellular carcinoma in patients with hepatitis C virus infection who achieved sustained virological response following interferon therapy: A large-scale, long-term cohort study, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 31巻, 5号, pp. 1009-1015, MAY 2016
  13. Usefulness of combining gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging and contrast-enhanced ultrasound for diagnosing the macroscopic classification of small hepatocellular carcinoma, EUROPEAN RADIOLOGY, 25巻, 11号, pp. 3272-3281, NOV 2015
  14. Efficacy and safety of the anticoagulant drug, danaparoid sodium, in the treatment of portal vein thrombosis in patients with liver cirrhosis, HEPATOLOGY RESEARCH, 45巻, 6号, pp. 656-662, JUN 2015
  15. Disseminated carcinomatosis of the bone marrow originating from hepatocellular carcinoma. A case report, HEPATOLOGY RESEARCH, 45巻, 6号, pp. 705-710, JUN 2015
  16. Evaluation of early response to hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma using the combination of Response Evaluation Criteria in Solid Tumors and tumor markers, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 30巻, 4号, pp. 726-732, APR 2015
  17. Non-invasive assessment of liver steatosis in non-alcoholic fatty liver disease, HEPATOLOGY RESEARCH, 44巻, 14号, pp. E420-E427, DEC 2014
  18. Interferon lambda 4 polymorphism affects on outcome of telaprevir, pegylated interferon and ribavirin combination therapy for chronic hepatitis C, HEPATOLOGY RESEARCH, 44巻, 14号, pp. E447-E454, DEC 2014
  19. Clinical outcome and prognostic factors of patients with hepatocellular carcinoma and extrahepatic metastasis treated with sorafenib, HEPATOLOGY RESEARCH, 44巻, 13号, pp. 1320-1328, DEC 2014
  20. Percutaneous transvenous embolization for portosystemic shunts associated with encephalopathy: Long-term outcomes in 14 patients, HEPATOLOGY RESEARCH, 44巻, 7号, pp. 740-749, JUL 2014
  21. Long-term outcome of patients with gastric varices treated by balloon-occluded retrograde transvenous obliteration, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 29巻, 5号, pp. 1035-1042, MAY 2014
  22. Efficacy and Safety of Sitagliptin for the Treatment of Nonalcoholic Fatty Liver Disease with Type 2 Diabetes Mellitus, HEPATO-GASTROENTEROLOGY, 61巻, 130号, pp. 323-328, MAR-APR 2014
  23. Clinical outcome of sorafenib treatment in patients with advanced hepatocellular carcinoma refractory to hepatic arterial infusion chemotherapy, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 28巻, 12号, pp. 1834-1841, DEC 2013
  24. Comparison of hepatic arterial infusion chemotherapy between 5-fluorouracil-based continuous infusion chemotherapy and low-dose cisplatin monotherapy for advanced hepatocellular carcinoma, HEPATOLOGY RESEARCH, 48巻, 13号, pp. 1118-1130, 201812
  25. Real-world efficacy of glecaprevir plus pibrentasvir for chronic hepatitis C patient with previous direct-acting antiviral therapy failures, JOURNAL OF GASTROENTEROLOGY, 54巻, 3号, pp. 291-296, 201903
  26. Levocarnitine Use Is Associated With Improvement in Sarcopenia in Patients With Liver Cirrhosis, HEPATOLOGY COMMUNICATIONS, 3巻, 3号, pp. 348-355, 201903
  27. The impact of interferon-free direct-acting antivirals on clinical outcome after curative treatment for hepatitis C virus-associated hepatocellular carcinoma: Comparison with interferon-based therapy, JOURNAL OF MEDICAL VIROLOGY, 91巻, 4号, pp. 650-658, 201904
  28. Comparison of intracellular responses between HBV genotype A and C infection in human hepatocyte chimeric mice, JOURNAL OF GASTROENTEROLOGY, 54巻, 7号, pp. 650-659, 201907
  29. Efficacy of glecaprevir and pibrentasvir treatment for genotype 1b hepatitis C virus drug resistance-associated variants in humanized mice, JOURNAL OF GENERAL VIROLOGY, 100巻, 7号, pp. 1123-1131, 201907
  30. Percutaneous transvenous shunt occlusion for portosystemic encephalopathy due to lenvatinib administration to a patient with hepatocellular carcinoma and portosystemic shunt, CLINICAL JOURNAL OF GASTROENTEROLOGY, 12巻, 4号, pp. 341-346, 201908
  31. Pruritus in patients with chronic liver disease and serum autotaxin levels in patients with primary biliary cholangitis, BMC GASTROENTEROLOGY, 19巻, 1号, 20191024
  32. Management of refractory ascites attenuates muscle mass reduction and improves survival in patients with decompensated cirrhosis, JOURNAL OF GASTROENTEROLOGY, 55巻, 2号, pp. 217-226, 202002
  33. Preoperative PET-CT is useful for predicting recurrent extrahepatic metastasis of hepatocellular carcinoma after resection, EUROPEAN JOURNAL OF RADIOLOGY, 124巻, 202003
  34. Successful retreatment with 12 weeks of glecaprevir and pibrentasvir for a genotype 2a HCV-infected hemodialysis patient who failed to respond to 8 weeks of prior glecaprevir and pibrentasvir therapy, CLINICAL JOURNAL OF GASTROENTEROLOGY, 13巻, 2号, pp. 267-270, 202004
  35. Circulating cytokines and angiogenic factors based signature associated with the relative dose intensity during treatment in patients with advanced hepatocellular carcinoma receiving lenvatinib, THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 12巻, 202005
  36. Incidence of microsatellite instability-high hepatocellular carcinoma among Japanese patients and response to pembrolizumab, HEPATOLOGY RESEARCH, 50巻, 7号, pp. 885-888, 202007
  37. Tumor Fibroblast Growth Factor Receptor 4 Level Predicts the Efficacy of Lenvatinib in Patients With Advanced Hepatocellular Carcinoma, CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY, 11巻, 202005
  38. Risk factors for histological progression of non-alcoholic steatohepatitis analyzed from repeated biopsy cases, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 35巻, 8号, pp. 1412-1419, 202008
  39. Ribavirin induces hepatitis C virus genome mutations in chronic hepatitis patients who failed to respond to prior daclatasvir plus asunaprevir therapy., J Med Virol., 92巻, 2号, pp. 210-218, Feb 2020
  40. Complete response to pembrolizumab in advanced hepatocellular carcinoma with microsatellite instability, CLINICAL JOURNAL OF GASTROENTEROLOGY, 13巻, 5号, pp. 867-872, 202010
  41. A case of advanced HCC treated with lenvatinib after hepatic arterial infusion chemotherapy combined with radiation therapy treatment for portal vein tumor thrombosis in the main trunk, CLINICAL JOURNAL OF GASTROENTEROLOGY, 13巻, 5号, pp. 839-843, 202010
  42. Impact of viral eradication by direct-acting antivirals on the risk of hepatocellular carcinoma development, prognosis, and portal hypertension in hepatitis C virus-related compensated cirrhosis patients, HEPATOLOGY RESEARCH, 50巻, 11号, pp. 1222-1233, 202011
  43. Analysis of Post-Progression Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib, ONCOLOGY, 98巻, 11号, pp. 787-797, 202011
  44. Real-world efficacy of sofosbuvir plus velpatasvir therapy for patients with hepatitis C virus-related decompensated cirrhosis, HEPATOLOGY RESEARCH, 50巻, 11号, pp. 1234-1243, 202011
  45. Abatacept treatment for patients with severe acute hepatitis caused by hepatitis B virus infection-Pilot study, JOURNAL OF VIRAL HEPATITIS, 28巻, 2号, pp. 400-409, 202102
  46. Signal Activation of Hepatitis B Virus-Related Hepatocarcinogenesis by Up-regulation of SUV39h1, JOURNAL OF INFECTIOUS DISEASES, 222巻, 12号, pp. 2061-2070, 20201215
  47. A case with life-threatening secondary sclerosing cholangitis caused by nivolumab, CLINICAL JOURNAL OF GASTROENTEROLOGY, 14巻, 1号, pp. 283-287, 202102
  48. Clinical Usefulness of Serum Autotaxin for Early Prediction of Relapse in Male Patients with Type 1 Autoimmune Pancreatitis, DIGESTIVE DISEASES AND SCIENCES, 66巻, 4号, pp. 1268-1275, 202104
  49. Efficacy of Lusutrombopag for Thrombocytopenia in Patients with Chronic Liver Disease Scheduled to Undergo Invasive Procedures, INTERNAL MEDICINE, 60巻, 6号, pp. 829-837, 2021
  50. A case of acute liver failure with echovirus infection diagnosed by a multi-virus real-time PCR system, IDCASES, 23巻, 2021
  51. Comparison of the Clinical Outcome of Ramucirumab for Unresectable Hepatocellular Carcinoma with That of Prior Tyrosine Kinase Inhibitor Therapy, ONCOLOGY, 99巻, 5号, pp. 327-335, 202104
  52. Novel drug resistance-associated substitutions against pibrentasvir emerged in genotype 1b hepatitis C virus-infected human hepatocyte transplanted mice, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 559巻, pp. 78-83, 20210625

招待講演、口頭・ポスター発表等

  1. B型肝炎ウイルス各種遺伝子型における感染性についての検討, 藤野 初江、柘植 雅貴、津島 健、坂宮 順子、盛生 慶、大野 敦司、中原 隆志、村上 英介、山内 理海、 河岡 友和、三木 大樹、平松 憲、茶山 弘美、今村 道雄、相方 浩、茶山 一彰, 第26回 肝細胞研究会, 2019年05月23日, 通常, 日本語
  2. Serum autotaxin levels is useful to evaluate fibrosis during entecavir therapy and to predict the development of hepatocellular carcinoma in patients with chronic Hepatitis B., Hatsue Fujino, Kei Morio, Atsushi Ono, Takashi Nakahara, Eisuke Murakami, Masami Yamauchi, Tomokazu Kawaoka, Daiki Miki, Masataka Tsuge, Hiromi Abe-Chayama, Hayes Clair Nelson, Michio Imamura, Hiroshi Aikata, Kazuaki Chayama, International HBV Meeting, 2019年, 通常, 英語, Melbourne
  3. Investigation of infectivity of serum-derived HBV from patients and human hepatocyte chimeric mouse to HepG2/NTCP cells., Hatsue Fujino, Maiko Namba, Atsushi Ono, Takashi Nakahara, Eisuke Murakami, Masami Yamauchi, Tomokazu Kawaoka, Daiki Miki, Masataka Tsuge, Hiromi Abe-Chayama, Hayes Clair Nelson, Michio Imamura, Hiroshi Aikata, Kazuaki Chayama, International HBV Meeting, 2019年, 通常, 英語, Melbourne
  4. 核酸アナログ内服中のB型慢性肝炎患者における肝線維化および発癌予測マーカーとしての血清オートタキシン濃度の有効性, 藤野 初江、相方 浩、茶山 一彰, 第61回日本消化器病学会大会, 2019年, 通常, 日本語
  5. C型慢性肝炎に対するTelaprevir/PegIFN/RBV併用療法の成績, 第99回日本消化器病学会 中国支部例会, 2013年06月15日, 通常, 日本語, 岡山
  6. IFNλ4遺伝子多型とTelaprevir/PRG-IFN/RBV治療効果の関係, 第17回日本肝臓学会大会, 2013年, 通常, 日本語, 東京
  7. C型慢性肝炎に対する最新の治療法, 第66回広島医学会総会, 2013年, 通常, 日本語
  8. Telaprevir/PEG-IFN/RBV療法施行中に急性膵炎を発症したC型肝硬変の1例, 第100回日本消化器病学会中国支部例会, 2013年, 通常, 日本語, 鳥取
  9. Vp3/4門脈腫瘍栓合併進行肝細胞癌に対する肝動注化学療法における門脈腫瘍栓への放射線療法の意義, 第40回日本肝臓学会西部会, 2013年, 通常, 日本語, 岐阜
  10. Telaprebir/PegIFN/RBV併用療法(難治例)の治療成績, 第100回消化器病学会総会, 2014年, 通常, 日本語, 東京
  11. 当科の肝硬変の成因別実態 前回調査との比較, 第50回日本肝臓学会総会, 2014年, 通常, 日本語, 東京
  12. Serum Autotaxin Levels Reflect Improvement of Liver Fibrosis in Patients with Chronic Hepatitis B during Entecavir Treatment., 2018年11月13日, 通常, 英語
  13. Hepatitis B Core-Related Antigen (HBcrAg) Is a Novel Risk Marker for Hepatocellular Carcinoma during Nucleoside Analoge Treatment., AASLD The liver meeting 2018, 2018年11月13日, 通常, 英語

受賞

  1. 2019年, Travel grant award, International HBV Meeting
  2. 2016年05月18日, 日本肝臓学会研究奨励賞, 日本肝臓学会